119 related articles for article (PubMed ID: 28730787)
21. Detection of miRNAs in urine of prostate cancer patients.
Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
[TBL] [Abstract][Full Text] [Related]
22. Furan and p-xylene as candidate biomarkers for prostate cancer.
Jiménez-Pacheco A; Salinero-Bachiller M; Iribar MC; López-Luque A; Miján-Ortiz JL; Peinado JM
Urol Oncol; 2018 May; 36(5):243.e21-243.e27. PubMed ID: 29395956
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
24. Capillary electrophoresis of urinary prostate glycoproteins assists in the diagnosis of prostate cancer.
Vermassen T; Van Praet C; Vanderschaeghe D; Maenhout T; Lumen N; Callewaert N; Hoebeke P; Van Belle S; Rottey S; Delanghe J
Electrophoresis; 2014 Apr; 35(7):1017-24. PubMed ID: 24254641
[TBL] [Abstract][Full Text] [Related]
25. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
26. The Urinary Sarcosine/Creatinine Ratio is a Potential Diagnostic and Prognostic Marker in Prostate Cancer.
Wang M; Zou L; Liang J; Wang X; Zhang D; Fang Y; Zhang J; Xiao F; Liu M
Med Sci Monit; 2018 May; 24():3034-3041. PubMed ID: 29741162
[TBL] [Abstract][Full Text] [Related]
27. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
[TBL] [Abstract][Full Text] [Related]
28. Urinary Nucleic Acid TSPAN13-to-S100A9 Ratio as a Diagnostic Marker in Prostate Cancer.
Yan C; Kim YH; Kang HW; Seo SP; Jeong P; Lee IS; Kim D; Kim JM; Choi YH; Moon SK; Yun SJ; Kim WJ
J Korean Med Sci; 2015 Dec; 30(12):1784-92. PubMed ID: 26713053
[TBL] [Abstract][Full Text] [Related]
29. Classification analyses for prostate cancer, benign prostate hyperplasia and healthy subjects by SERS-based immunoassay of multiple tumour markers.
Zhou L; Liu Y; Wang F; Jia Z; Zhou J; Jiang T; Petti L; Chen Y; Xiong Q; Wang X
Talanta; 2018 Oct; 188():238-244. PubMed ID: 30029370
[TBL] [Abstract][Full Text] [Related]
30. Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia.
Fu S; Zhang X; Niu Y; Wang RT
Asian Pac J Cancer Prev; 2018 Mar; 19(3):699-702. PubMed ID: 29580043
[TBL] [Abstract][Full Text] [Related]
31. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
32. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
[TBL] [Abstract][Full Text] [Related]
33. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
34. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
Gao ZW; Liu G; Sheng BW
Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
[TBL] [Abstract][Full Text] [Related]
35. Prostate-specific antigen: insufficient discrimination between benign prostatic hyperplasia and organ-confined prostate cancer.
Wolff JM; Boeckmann W; Borchers H; Handt S; Reineke T; Jakse G
Urol Int; 1996; 57(3):170-4. PubMed ID: 8912446
[TBL] [Abstract][Full Text] [Related]
36. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
Xu Y; Qin S; An T; Tang Y; Huang Y; Zheng L
Prostate; 2017 Jul; 77(10):1167-1175. PubMed ID: 28617988
[TBL] [Abstract][Full Text] [Related]
37. Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH.
Yun SJ; Yan C; Jeong P; Kang HW; Kim YH; Kim EA; Lee OJ; Kim WT; Moon SK; Kim IY; Choi YH; Kim WJ
Ann Surg Oncol; 2015 Jul; 22(7):2439-45. PubMed ID: 25348783
[TBL] [Abstract][Full Text] [Related]
38. Development of an ELISA for sPSP94 and utility of the sPSP94/sPSA ratio as a diagnostic indicator to differentiate between benign prostatic hyperplasia and prostate cancer.
Mhatre DR; Mahale SD; Khatkhatay MI; Desai SS; Jagtap DD; Dhabalia JV; Tongaonkar HB; Desai MP; Dandekar SP; Varadkar AM
Clin Chim Acta; 2014 Sep; 436():256-62. PubMed ID: 24952364
[TBL] [Abstract][Full Text] [Related]
39. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
Stephan C; Lein M; Jung K; Schnorr D; Loening SA
Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
[TBL] [Abstract][Full Text] [Related]
40. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]